Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04585035 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate D-1553 in Subjects With Solid Tumors
A Phase 1 study of Solid Tumor, Adult and NSCLC, sponsored by InventisBio Co..
- Active
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT04585035: Active Phase 1 study of Solid Tumor, Adult and NSCLC, sponsored by InventisBio Co..
NCT04585035 is a Phase 1 study of Solid Tumor, Adult and NSCLC that is active but no longer recruiting, run by InventisBio Co.. The registered enrollment target is 180 participants, roughly in line with the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04585035, a Phase 1 study of Solid Tumor, Adult and NSCLC, is active but no longer recruiting, sponsored by InventisBio Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.
Conditions Studied
Interventions
- DRUG D-1553
- DRUG D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
Study Locations (20)
New South Wales
- Research Site - Blacktown
- Research Site - East Albury
- Research Site - Kogarah
- Research Site - Waratah
California
- Research Site - Fresno
- Research Site - Orange
- Research Site - San Francisco
Victoria
- Research Site - Fitzroy
- Research Site - Frankston
- Research Site - Malvern
Other
- Research Site - Seoul
- Research Site - Seoul
Kentucky
- Research Site - Louisville
Michigan
- Research Site - Detroit
New York
- Research Site - New York
Oregon
- Research Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT04585035 still lists
NCT04585035 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target.
The record links to 3 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 2 interventions - of which D-1553 is the first listed.
NCT04585035 names 20 study sites across 12 states, led by New South Wales, California, Victoria.
Frequently Asked Questions
What is clinical trial NCT04585035 about?
NCT04585035 is a clinical study titled "Study to Evaluate D-1553 in Subjects With Solid Tumors". This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.
What is the current status of trial NCT04585035?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2020-10-02. Estimated completion is 2025-12.
What conditions does trial NCT04585035 study?
This clinical trial studies the following conditions: Solid Tumor, Adult, NSCLC, CRC.
What interventions are being tested in trial NCT04585035?
The interventions under investigation include: D-1553 (DRUG), D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other (DRUG).
Who is sponsoring clinical trial NCT04585035?
This trial is sponsored by InventisBio Co., which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04585035 being conducted?
This trial has 20 study locations across California, Kentucky, Michigan, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04585035's enrollment target sits among peer trials
180 27th of 72 higher than 46 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI